Clinical Trial Update: Onabotulinum Dose Comparison in Chronic Migraine Superior to 100 Units? [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether higher doses of onabotulinumtoxinA are superior to 100 units for chronic migraine; the study is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• OnabotulinumtoxinA (botulinum toxin type A)

Snippet

Sponsor: United States Naval Medical Center, San Diego | Conditions: Chronic Migraine, Headache | Phase 3 | Status: TERMINATED